Listed

Anaptysbio, Inc: Form 10-KT, filed Sep 21, 2026

Filed with the SEC on Sep 21, 2026 and accepted by EDGAR at Sep 21, 2026, 16:23 ET.

Share

Sections

Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2026-06-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue6 months2026-01-01 to 2026-06-30$53.0mus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Operating income6 months2026-01-01 to 2026-06-30$32.3mus-gaap:OperatingIncomeLoss
Income tax6 months2026-01-01 to 2026-06-30−$181.5mus-gaap:IncomeTaxExpenseBenefit
Net income6 months2026-01-01 to 2026-06-30$131.0mus-gaap:NetIncomeLoss
Diluted EPS6 months2026-01-01 to 2026-06-30$3.50us-gaap:EarningsPerShareDiluted
Basic EPS6 months2026-01-01 to 2026-06-30$4.52us-gaap:EarningsPerShareBasic
Diluted shares (weighted)6 months2026-01-01 to 2026-06-3037,476,000 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow6 months2026-01-01 to 2026-06-30−$52.6mus-gaap:NetCashProvidedByUsedInOperatingActivities
Share repurchases6 months2026-01-01 to 2026-06-30$0us-gaap:PaymentsForRepurchaseOfCommonStock
Cash and equivalentsAt period end2026-06-30$133.8mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2026-06-30$198.4mus-gaap:AssetsCurrent
Total assetsAt period end2026-06-30$317.0mus-gaap:Assets
Current liabilitiesAt period end2026-06-30$35.4mus-gaap:LiabilitiesCurrent
Shareholders' equityAt period end2026-06-30$10.6mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001193125-26-396696. Last ingested by Listed: Nov 13, 2026, 16:10 ET. Listed shows no prices and gives no investment advice.